J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...

Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...

Giancarlo Benelli brings over two decades of experience in the pharmaceutical industry, rooted in his unique journey from ...

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

Anderson is expecting 2025 to be a pivotal year for his turnaround plan – which revolves around the removal of management ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

Giuseppe Accogli became the Group CEO of Chiesi Pharmaceuticals in 2023. With a 25-year career in the med-tech industry, he ...